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Abstract
Purpose A single-agent dose-escalating phase I and phar-
macokinetic study on TSU-68, a novel multiple receptor
tyrosine kinase inhibitor, was performed to determine the
safety proWle, maximum-tolerated dose for Japanese
patients with advanced solid tumors and to deWne the rec-
ommended dose of phase II studies.
Methods Study design was a dose escalation method on a
three-patient cohort. TSU-68 was given orally twice daily
(bid) between meals without interruption; the estimation of
dose escalation was based on the toxicity within 4 week
administration at each dose level.
Results Fifteen patients were enrolled into the study.
Dose levels studied were 200, 400, 800, and 1,200 mg/m2
bid. Grade 3 arrhythmia and anemia/thrombocytopenia
were observed in 1 patient each at 800 mg/m2 bid. Three
patients discontinued continuous oral administration for
4 weeks at 400 and 800 mg/m2 bid. At 1,200 mg/m2 bid, 2
patients discontinued the treatment over 4 weeks for intol-
erable fatigue and abdominal pain, respectively. No serious
drug-related toxicities have been observed. Grade 1–2 tox-
icity included urinary/feces discoloration, diarrhea, fatigue,
anorexia, abdominal/chest pain, and edema. Tumor shrink-
age was observed in 1 patient of NSCLC. In the pharmaco-
kinetics, at any dose levels, Cmax and AUC0–t after repeated
administration of TSU-68 on days 8 and 29 were »2-fold
lower that those after the Wrst administration on day 1; these
parameters are similar between days 8 and 28. In addition,
no obvious dose-dependent increase in plasma exposure to
TSU-68 repeatedly administered was observed over the
four dose levels, including the higher dose levels.
Conclusions The tolerable dose in this administration
schedule for continuing treatment is thought to be 800 mg/m2
or less bid.
Keywords Receptor tyrosine kinase inhibitor · 
Solid tumors · Phase I · Pharmacokinetic
Introduction
Angiogenesis, the growth of new blood vessels from exist-
ing host vasculature, plays a central role in a variety of
physiologic and pathologic states. Several families of RTKs
such as vascular endothelial growth factor (VEGF), Wbroblast
growth factor (FGF), and platelet-derived growth factor
(PDGF) receptors have been implicated in this process and
Y. Ueda · T. Shimoyama · H. Murakami · N. Yamamoto · 
Y. Yamada · T. Tamura (&)
Division of Medical Oncology, 
National Cancer Center Hospital, 5-1-1, Tsukiji, 
Chuo-ku, Tokyo 104-0045, Japan
e-mail: ttamura@ncc.go.jp
H. Arioka
Department of Medical Oncology, 
Yokohama Rosai Hospital, 
Yokohama, Kanagawa, Japan
Y. Ueda
Department of Internal Medicine, 
Kagawa Prefectural Central Hospital, Takamatsu, 
Kagawa, Japan
T. Shimoyama
Department of Chemotherapy, 
Tokyo Metropolitan Cancer and Infectious Diseases 
Center Komagome Hospital, Tokyo, Japan
H. Murakami
Thoracic Oncology Division, 
Shizuoka Cancer Center, Shizuoka, Japan1102 Cancer Chemother Pharmacol (2011) 67:1101–1109
123
are involved in diverse developmental and oncogenic
processes. VEGF has been shown to be the central positive
regulator of tumor angiogenesis, since it is reported that the
production of VEGF may be increased in many solid
tumors and the ability of production may be correlated with
the number of blood vessels and prognosis in breast caner,
stomach cancer, colon cancer, lung cancer, and others
[1–4]. VEGF signaling is an attractive therapeutic target,
and the antibodies and inhibitors speciWcally directed
against VEGF and/or its receptor VEGFR2 have been dem-
onstrated to potently prevent vasculature and the growth of
a large number of experimental tumor types [5, 6]. FGF and
PDGF also play critical roles in angiogenesis, sometimes in
concert with VEGF. The prototype FGF family member,
FGF2, is a potent mitogen of diVerent cell types including
vascular endothelial cells, Wbroblasts, and tumor cells,
along with its receptors, in a variety of human tumor types
[7, 8]. Additionally, FGF2 has been reported to be synergis-
tic with VEGF and to induce the expression of VEGF [9].
FGF is one of the alternative angiogenesis factors during
the resistance of VEGF-targeting therapy. PDGF and its
receptors have been detected in diverse human cancers, and
PDGFRs are expressed on tumor neovasculature and up-
regulated during tumor progression [10, 11]. PDGF stimu-
lates angiogenesis by up-regulating VEGF production and
modulating the proliferation of pericytes and Wbroblast-like
cells surrounding the endothelium [12,  13]. Circulating
PDGF has been associated with metastases and higher
microvessel counts [14, 15].
The signaling cascades generated by these three
ligands and their respective receptors are complex,
directly and indirectly aVecting tumor angiogenesis and
tumor growth. In light of the important role of VEGF,
FGF, and PDGF and their receptors in tumor angiogenesis
and in survival of existing endothelial cells, it is reason-
able to expect that simultaneously antagonizing the
VEGF, FGF, and PDGF signaling pathways may be more
eVective than antagonizing one signal transduction alone.
TSU-68 is a novel small molecule that competitively
inhibits the tyrosine kinase of the receptors for VEGF,
basic FGF, and PDGF. TSU-68 has signiWcant antitumor
activity against many types of tumor xenograft explants in
athymic mice [16]. TSU-68 inhibits angiogenesis through
several mechanisms, including the induction of apoptosis
in vascular endothelial cells and tumor cells, resulting in
perturbing existing tumor vascular function and also
inhibiting newly synthesis angiogenesis for the tumor
growth [17].
On the basis of these preclinical antiangiogenic and anti-
tumor data, we planned a phase I study of TSU-68 in
patients with advanced solid tumors using a continuous
twice daily between meals oral administration regimen.
Patients and methods
Study population
Patients with a cytologically or histologically conWrmed
diagnosis of a solid tumor refractory to standard treatment
or for whom no standard therapy was available were eligi-
ble for this study. Patients with symptomatic brain metas-
tases were excluded. Further eligibility criteria included
the following: age ¸20 years and ·75 years; World
Health Organization performance status of ·2; life expec-
tancy of ¸60 days; no anticancer therapy in the previous
4 weeks; no serious complication (ileus, myocardial
infarction, lung Wbrosis, and so on); no past history of
thrombosis; adequate function of bone marrow (hemoglo-
bin ¸8.0 mg/dl, absolute white blood cell count ¸4,000/
mm3 or neutrophil count ¸2,000/mm3, and white blood
cell count ·12,000/mm3); liver (bilirubin ·1.5 mg/dl;
AST and ALT ·100 IU/ml); renal (creatinine clearance
¸50 ml/min); lung (PaO2 ¸65 mmHg); and ability to take
oral medication. Local ethics boards approved the proto-
col and informed-consent brochures in accordance with
the Declaration of Helsinki and Good Clinical Practice
Guidelines. All patients gave written informed consent at
study entry.
Study design
This study was an open, non-randomized, non-comparative,
dose-escalation method on three-patient cohort to adult
patients with advanced solid tumors. The trial was designed
to comply with the ethical principals of Good Clinical Prac-
tice in accordance with the Declaration of Helsinki.
The estimation of dose escalation was based on the tox-
icity within 4 week administration at each dose level. If no
grade 2 toxicity was observed at the previous dose level, a
100% dosage increment was allowed, and if no dose-limit-
ing toxicity (DLT) was observed, a 40% dosage increment
was allowed. However, if DLT was observed, a 33% dos-
age increment was allowed. At each dose level, the third
patient was required to have 14 days of treatment before
escalation was allowed. Once DLT was seen in one patient
at a given dose level, an additional 3 patients had to be
treated at that dose level before further dose escalation was
allowed. DLT was deWned as drug-related adverse events
according to National Cancer Institute-Common Toxicity
Criteria version 2.0 (NCI-CTC) [18] and comprised any
grade 3/4 non-hematologic toxicity and grade 4 hemato-
logic toxicity. The maximum-tolerated dose (MTD) was
deWned as the dose that induced DLTs in more than 33% of
patients during 4 weeks. No intra-patient dose escalation
was allowed.Cancer Chemother Pharmacol (2011) 67:1101–1109 1103
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Drug administration
TSU-68, (Z)-3-[2,4-dimethyl-5-(2-oxo-1,2-dihydro-indol-
3-ylidenemethyl)-1H-pyrrol-3-yl]-propionic acid was obtained
from Taiho Pharmaceutical Co., Ltd. The starting dosing
(200 mg/m2 twice daily) of Japanese patients was calcu-
lated based on the safety results of 4 week toxicology stud-
ies in rats and referred to the precedence phase I study of
Caucasian patients. At the Wrst day of treatment, patients
were given a single dose for pharmacokinetic purposes. The
tablet was swallowed immediately more than 2 h after
breakfast and supper. Patients were instructed to record
their daily amount of tablets taken, the timing in relation to
their meals. TSU-68 was taken for 28 consecutive days and
was continued in case of stable disease or disease remission
after this period for as long as no disease progression and/or
no unacceptable drug-related toxicity were seen. Routine
antiemetics were not prescribed. TSU-68 administration
was immediately interrupted at the occurrence of DLT.
Patient assessment and follow-up treatment
Before therapy, a complete medical history was taken and a
physical examination was performed. A complete blood
count, including WBC diVerential, and serum chemistry,
including sodium, potassium, chloride, calcium, urea, creati-
nine, protein, albumin, bilirubin, aspartate aminotransferase,
alanine aminotransferase, alkaline phosphatase, gamma-glut-
amyl transpeptidase, and lactate dehydrogenase, were per-
formed, as were urine analysis, Electrocardiogram, and Chest
X-ray. In addition, tumor markers related to the tumor type
were measured. Weekly evaluations included history, physi-
cal examination, a toxicity assessment according to NCI-
CTC, complete blood count, serum chemistries, and urine
analysis. Tumor measurements were performed before treat-
ment, at 4 weeks, and were evaluated according to the Japan
Society for Cancer Therapy criteria [19], which was estab-
lished based on World Health Organization (WHO) criteria.
The criteria for the evaluation of antitumor eVects were as fol-
lows: complete response (CR), eradication of all cancers and
maintenance of the condition for 4 weeks or more; partial
response (PR), 50% or more reduction in size of lesions and
maintenance of the condition for 4 weeks or more; no change
(NC), less than 50% reduction in size of lesions or enlarge-
ment of lesions within 25% and maintenance of the condition
for 4 weeks or more; progressive disease (PD), 25% or more
enlargement of lesions or appearance of new lesions. In case
of progressive disease, patients were taken oV the study.
Pharmacokinetic and biomarker sampling
For the pharmacokinetic evaluation, TSU-68 was adminis-
tered once a day on days 1 and 29 and twice a daily during
days 2–28. Blood samples were collected within about
30 min before dosing and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, and
12 h after dosing on days 1, 8 and 29. Regarding days 1 and
29, blood samples were also collected at 24 h after dosing.
These samples were immediately centrifuged at 3,000 rpm
for 10 min at 4°C, after which obtained plasma samples
were frozen at ¡20°C until analysis. Urine samples were
collected at the following intervals for measurement of
TSU-68: before dosing on day 1, 0–12 and 12–24 h after
dosing on days 1 and 29 and 0–12 h after the 1st dosing on
day 8. In addition, angiogenesis-related factors such as
plasma VEGF, E-selectin, tissue-type plasminogen activa-
tor (tPA), vascular cell adhesion molecule-1 (VCAM-1),
plasminogen activator inhibitor-1 (PAI-1), and urine VEGF
were measured on days 1, 8, and 29.
Pharmacokinetic and biomarker analyses
The pharmacokinetic samples were measured by MDS
Pharma Services (Montreal, Canada), and biomarker sam-
ples were measured by SRL, Inc. (Tokyo, Japan). TSU-68
concentration was determined using a validated high-per-
formance liquid chromatography method with UV detec-
tion, with a lower limit of quantiWcation of 0.1 g/mL.
Non-compartmental pharmacokinetic parameters including
area under the plasma concentration–time curves (AUC)
from time 0 to the last measurable time (AUC0–t), maxi-
mum concentration (Cmax), time to maximum concentration
(Tmax), and elimination half-life (T1/2) were calculated
using PhAST (Ver.2.3, MDS Pharma Services, Montreal,
Canada).
Statistical analysis
A regression approach was applied to evaluate dose propor-
tionality in pharmacokinetic parameters. Variability in
pharmacokinetics between administration days was evalu-
ated by either the paired Student’s t-test or an analysis of
variance. Statistical signiWcance was considered to be
reached at P < 0.05. The analysis was performed using the
SAS®.
Results
Patient characteristics
Fifteen patients were enrolled in this study between
November 2000 and June 2001. All patients were Japanese.
Details of dosage level were 3 patients at 200 mg/m2 bid, 3
patients at 400 mg/m2 bid, 6 patients at 800 mg/m2 bid, and
3 patients at 1,200 mg/m2 bid. Patient characteristics are
listed in Table 1. There were 5 men and 10 women with a1104 Cancer Chemother Pharmacol (2011) 67:1101–1109
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median age of 52 years (range, 27–64 years). All patients
were evaluated for safety and pharmacokinetic analyses.
Three patients discontinued continuous oral administration
for 4 weeks due to adverse events (one patient at 800 mg/
m2) and disease progress (two patients at 400 mg/m2 and
800 mg/m2). In addition, Wve patients continued the medi-
cation after 4 weeks, and these included two patients of
dose reduction from 1,200 mg/m2 to 800 mg/m2.
Dose escalation and maximum-tolerated dose
The dosage was increased from 200 to 400, 800, and
1,200 mg/m2 bid by cohort of three patients. At a dosage
level of 1,200 mg/m2 bid, two patients discontinued the
treatment over 4 weeks for intolerable grade 2 fatigue or
grade 2 abdominal pain, which were not critical in evaluat-
ing the dose escalation for 4 weeks. These two patients of
grade 2 toxicities could continue drug administration for
4 weeks (one cycle); however, both patients had to reduce
the dosage level to 800 mg/m2 bid from the next cycle, and
1,200 mg/m2 bid demonstrated unacceptable adverse events
for an antitumor drug that is used by long-term consecutive
oral administration. On the basis of the results of the phar-
macokinetic data, increase in the dosage was terminated,
and the three additional patients were administered at a
lower dosage of 800 mg/m2 bid. At a dosage level of
800 mg/m2 bid, one patient was conWrmed DLT into a total
of six patients. In addition, two patients at 1,200 mg/m2
could continue TSU-68 administration with a reduction to
800 mg/m2 after 4 weeks. Thus, protocol-deWned MTD was
1,200 mg/m2 bid, and the acceptable dosage level was esti-
mated 800 mg/m2 bid in daily administration.
Dose-limiting toxicity and safety proWle
There was one protocol-deWned DLT as grade 3 arrhythmia
at the dosage level of 800 mg/m2 bid. The patient had a
complication with supraventricular arrhythmia but had
already been controlled by continuous administration of an
antiarrhythmic agent. No other DLTs were recorded.
The major drug-related adverse events for 4 week
administration with highest grade pre-event per patient are
listed in Table 2. Main toxicities of subjective and objective
symptom were diarrhea, fatigue, anorexia, nausea, and
vomiting. At lower doses, these symptoms were usually
mild and required no speciWc treatment. Six patients
experienced grade 1/2 tumor pain in diverse pain events.
Edema and/or pleural eVusion progression were seen in 7
patients. In addition, other toxicities consisted of grade 1
urinary/feces discoloration based on drug color (such as
saVron yellow).
Drug-related abnormal changes in laboratory values
were observed in grade 3 anemia and thrombocytopenia
from day 27 in one patient at 800 mg/m2 bid. Other toxici-
ties experienced in laboratory values were grade 1/2 hypo-
albuminemia, grade 1 alkaline phosphatase elevation, and
transient grade 1 transaminase elevation.
Four episodes of atrial rhythm abnormalities (atrial
Wbrillation in a patient and sinus tachycardia in 3 patients
with previous cardiac history) were seen. Each patient at
200 mg/m2 or 1,200 mg/m2 experienced grade 2 supraven-
tricular arrhythmia or grade 1 arrhythmia; these events
were of a transient manner, and there was no relationship to
TSU-68. One patient of grade 3 supraventricular arrhyth-
mia at 800 mg/m2 and one patient of grade 2 atrial Wbrilla-
tion and grade 1 sinus tachycardia at 1,200 mg/m2 were
treated with medication, and there was a relationship to
TSU-68. One patient of grade 3 supraventricular arrhyth-
mia (DLT) with sinus tachycardia (heart rate over 160/min)
occurred on day 6, although this patient had taken verapa-
mil for a long time. TSU-68 treatment was discontinued,
and he was treated with digoxin in addition to verapamil
dose-up. Subsequently, heart rate was decreased to about
80/min.
Pharmacokinetics
Pharmacokinetic studies were performed in 15 patients at
doses from 200 to 1,200 mg/m2. The mean concentration–
time proWles in each dosage are shown in Fig. 1. Pharmaco-
kinetic results are presented in Table 3. The relationship
between the dose and mean Cmax or AUC0-t is plotted in
Fig. 2. After the Wrst dose, the plasma concentration of
Table 1 Patients characteristics
* Including cervical cancer, retroperitoneal cancer, intestinal cancer
and sarcoma of uterus
Characteristic Patients number (%)
(15 patients)
Gender
Male 5 (33)
Female 10 (67)
Age (Years)
Median 52.0
Range 27–64
Performance status
01 ( 7 )
11 4 ( 9 3 )
20 ( 0 )
Tumor type
NSCLC 6 (40)
Colorectal 3 (20)
Thymoma 2 (13)
Others* 4 (27)Cancer Chemother Pharmacol (2011) 67:1101–1109 1105
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Table 2 Number of patients with drug-related adverse events for 28-days administration (highest grads per event per patients)
G common toxicity criteria grade 1 is mild, a grade 2 is moderate, and grade 3 is severe
* The advanced events listed here were reported in >20% of patients and the grade 3 events of patient
** Number of patients with drug-related adverse events after 28 days (200 mg/m2 bid; N = 1,400 mg/m2 bid; N = 1,800 mg/m2 bid; N =3 )
Adverse events 200 mg/m2 
bid (N =3 )
400 mg/m2 
bid (N =3 )
800 mg/m2 
bid (N =6 )
1,200 mg/m2 
bid (N =3 )
Total* 
(N =1 5 )
Total** 
(N =5 )
G1 G2 G3 G1 G2 G3 G1 G2 G3 G1 G2 G3 N (%) N (%)
U r i n e  d i s c o l o r a t i o n 3––3––6––3 – – 1 5 ( 1 0 0 ) 5 ( 1 0 0 )
D i a r r h e a 3––1––22–1 1 – 1 0 ( 6 7 ) 3 ( 6 0 )
F e c e s  d i s c o l o r e d –––1––6––3 – – 1 0 ( 6 7 ) 4 ( 8 0 )
F a t i g u e 1––1––31–2 1 – 9 ( 6 0 ) 4 ( 8 0 )
A n o r e x i a ––––––31–2 1 – 7 ( 4 7 ) 1 ( 2 0 )
A b d o m i n a l  p a i n ––––––21–1 1 – 5 ( 3 3 ) 1 ( 2 0 )
F a c e  e d e m a 1––1––1––2 – – 5 ( 3 3 ) 3 ( 6 0 )
N a u s e a 1–––––2––– 1 – 4 ( 2 7 ) 1 ( 2 0 )
U p p e r  a b d o m i n a l  p a i n 1–––1––––2 – – 4 ( 2 7 ) – –
C h e s t  p a i n –1–1–––––1 – – 3 ( 2 0 ) 2 ( 4 0 )
Vomiting ––––––2––– 1 – 3 ( 2 0 ) 1 ( 2 0 )
Alkaline phosphatase 
increased
1––1––3––1 – – 6 ( 4 0 ) 2 ( 4 0 )
A l b u m i n  d e c r e a s e d ––––1–4––– 1 – 6 ( 4 0 ) – –
Alanine aminotransferase 
increased
1–––––2––– – – 3 ( 2 0 ) 3 ( 6 0 )
T o t a l  p r o t e i n  d e c r e a s e d––––––3––– – – 3 ( 2 0 ) – –
A r r h y t h m i a ––––––––1– – – 1 ( 7 )1 ( 2 0 )
A n e m i a ––––––––1– – – 1 ( 7 )– –
T h r o m b o c y t o p e n i a –––––––1– – – 1 ( 7 )– –
Fig. 1 Plasma concentration-versus-time proWle of TSU-68
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TSU-68 increased to reach Cmax at »2.5 h and thereafter
disappeared with T1/2 in »8–10 h. At the any dose levels,
Cmax and AUC0–t after the repeated doses on days 8 and 29
were »2-fold lower than those after the Wrst doses on day 1.
These parameters are not statistically diVerent between
days 8 and 29. In addition, no obvious dose-dependent
increase in plasma exposure to TSU-68 repeatedly adminis-
tered was observed over the four dose levels, most notably
the higher dose levels. Urinary excretion of TSU-68 was
below 1% of dose at the any dose levels.
Response
No partial or complete responses were seen. One patient with
adenocarcinoma of the lung had a minor response by 4 week
treatment (Fig. 3) and continued 3 months, but after that the
treatment discontinued because of tumor progression and
drug-related toxicity. The increased eVusion was conWrmed
non-malignant, and this event was considered a drug-related
toxicity. The size of the target lesion reduced from
5.5 cm £ 5.0 cm of the base line to 4.5 cm £ 4.3 cm of
4 week treatment (29.6% reduction). Reduction of tumor
marker levels was seen in the same patient (CEA
22.6 ! 12.6 ng/ml, SLX 74 ! 58 U/ml). Four patients had
stable disease (non-small cell lung cancer 2; thymoma 1; per-
itoneal sarcoma 1) and continued treatment over two cycles
until disease progression (until 5 cycle for patients with peri-
toneal sarcoma and 2 cycles for the rest of the patients).
In the angiogenesis-related biomarker of the six tested
factors with 14 patients, not including one patient of DLT,
Table 3 Pharmacokinetic 
parameters of TSU-68 after day 
1, day 8, or day 29 
administration
PK Parameter Dose 
(mg/m2)
Pts. 
no.
Day 1 Day 8 Day 29
Tmax (h) 200 3 2.3 § 1.5 1.7 § 0.3 1.7 § 0.8
400 3 2.5 § 1.3 1.8 § 0.3 1.0*
800 6 2.8 § 1.1 1.5 § 0.4** 2.1 § 0.3***
1,200 3 2.2 § 0.8 1.8 § 0.3 1.7 § 0.3
Cmax (g/mL) 200 3 10.552 § 6.042 6.669 § 3.698 6.354 § 3.775
400 3 11.667 § 3.807 7.212 § 1.060 6.351*
800 6 14.620 § 5.649 10.564 § 1.831** 10.732 § 4.690***
1,200 3 16.004 § 1.910 8.148 § 4.219 6.706 § 0.884
AUC0–t (g h/mL) 200 3 45.6 § 21.0 20.6 § 6.2 21.2 § 9.5
400 3 58.2 § 16.8 25.0 § 9.4 22.9*
800 6 83.3 § 32.7 44.6 § 17.3** 30.0 § 16.7***
1,200 3 76.6 § 1.0 32.9 § 16.2 25.8 § 2.4
T1/2 (h) 200 3 8.03 § 3.82 4.80 § 2.14 3.59 § 1.71
400 3 7.89 § 4.04 3.53 § 0.43 5.36*
800 6 9.93 § 6.01 4.31 § 2.72** 4.37 § 4.05***
1,200 3 8.33 § 4.65 2.78 § 0.90 4.84 § 3.29
* 2 patients, ** 5 patients, 
*** 4 patients
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an average of PAI-1 and urine VEGF saw an increase of
more than 20% over the baseline (from 24.3 § 6.7 ng/ml to
29.5 § 11.3 ng/mL and from 96.6 § 62.4 pg/ml to 132.1 §
93.6 pg/mL, respectively), but plasma VEGF, E-selectin,
tPA and VCAM-1 were not changed substantially.
Discussion
We performed a phase I and pharmacokinetic study to
explore safety, tolerated dose, and pharmacokinetics of the
oral multiple tyrosine kinase inhibitor TSU-68 in Japanese
patients with advanced solid tumors. In this study using
continuous oral bid administration between meals, side
eVects attributable to the study drug were subjective/objec-
tive symptom and abnormal changes in laboratory values,
whereas DLT included arrhythmia.
The subjective and objective symptom toxicities of
TSU-68 in our current study were predominantly gastroin-
testinal and consisted of dose-dependent, non-cumulative,
and reversible diarrhea, fatigue, anorexia, and abdominal
pain. At lower dose levels, these symptoms were mild and
needed no additional treatment. At the highest dose level, 2
patients discontinued the treatment over 4 weeks for intol-
erable fatigue and abdominal pain, respectively (Table 2).
Some patients with abdominal pain were given gastrointes-
tinal endoscopy, but no remarkable Wnding was observed. It
was considered a reasonable assessment to stop the dose
escalation under grade 2 fatigue and grade 2 abdominal
pain at a dosage level of 1,200 mg/m2 bid, because of unac-
ceptable adverse events for an antitumor drug that is used in
long-term consecutive oral administration.
In 7 patients, edema and/or pleural eVusion progression
were seen as dose independent (for example: Fig. 3).
Edema was remarkable on the face and eyelids. In addition,
11 patients experienced hypoalbuminemia dose depen-
dently. Although this was seen from an early period, it
improved immediately after therapy discontinuance.
Although VEGF is also known as a vascular permeability
factor [20, 21], the contribution of VEGF is unclear with no
signiWcant diVerence between patients with edema or eVu-
sion progression and patients without. VEGF level in pleu-
ral eVusion was not elevated in some patients (data not
shown). On the other hand, there is a possible contribution
of PDGF in this phenomenon based on the report that
edema was seen in about 40% patients including 7% grade
3/4 treated with Imatinib, which is an inhibitor of Bcr/Abl
tyrosine kinase and PDGF/Kit tyrosine kinase and
approved for chronic myeloid leukemia, Philadelphia chro-
mosome positive acute lymphoblastic leukemia and gastro-
intestinal stromal tumor [22–24]. It was also reported that
PDGF levels of pleural eVusion with lung cancer were
higher than in non-malignant pleural eVusions [25].
Six patients experienced tumor pain progression such as
chest pain from primary or metastatic lung cancer. This
may be due to drug intake, because tumor pain was dimin-
ished after being taken oV the drug. To clarify the mecha-
nism of these symptoms, additional studies including basic
research are needed.
The hematologic toxicity of TSU-68 in the current study
was considered dose independent. Grade 3 anemia and
thrombocytopenia were seen in the same patient at 800 mg/
m2 dose level. Thrombocytopenia was recovered to pre-
treatment level after treatment discontinuance, but anemia
continued. This patient was given radiotherapy after 9 days
due to bone metastasis. Therefore, anemia was not attrib-
uted to TSU-68 intake but tumor progression.
These toxicity Wndings, characterized as edema, were
much diVerent from the reports of recent approved and
developing angiogenesis inhibitors showing bleeding, per-
foration, hypertension, hand-foot syndrome, and some leu-
kocytopenia as the distinguishing toxicity proWle [26–28].
In the pharmacokinetics, the Cmax and AUC were similar
between days 8 and 29, although decreased by half after the
Fig. 3 Computed tomography 
scan of a tumor minor shrinkage 
in a patient with adenocarci-
noma of the lung, and pleural 
eVusion progression, treated 
with TSU-68. a Baseline; 
b week 4. White arrow primary 
tumor in the lung1108 Cancer Chemother Pharmacol (2011) 67:1101–1109
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repeated administration of TSU-68. This suggests that the
decreased plasma exposure to TSU-68 rapidly reaches the
steady state and is maintained over therapeutic cycles. This
trend is consistent with a published clinical result showing
that AUC of TSU-68 on day 56 was similar to that on day
28 [29]. In addition, at the higher dose levels, there was no
dose-dependent increase in these parameters of TSU-68
repeatedly administered, which is probably due to a satura-
tion of absorption. The trough plasma level in the steady-
state exposure to 200 mg/m2 TSU-68 is above the IC50 for
VEGF and PDGF receptors cellular assay, and the exposure
was also comparable with that showing eYcacy in human
cancer xenograft models [16]. The decrease in the exposure
after repeated administration is probably due to autoinduc-
tion of TSU-68 metabolism. Since urinary excretion
accounted for a very low percentage of the dose, predomi-
nant elimination of TSU-68 can be regarded as hepatic
metabolism. Non-clinical studies [30,  31] suggest that
TSU-68 causes induction of liver cytochrome P450,
CYP1A1/2 involved in its own metabolism, leading to the
decrease in the TSU-68 plasma concentrations.
A phase I study of the United States was reported before
our Japanese study. Nineteen Caucasian patients were
treated at doses ranging from 400–1,200 mg/m2 fasted and
100–400 mg/m2 fed by twice daily administration [32].
Dose-limiting toxicities including fatigue, pleuritic chest
pain, shortness of breath, and pericardial eVusions were
seen in 2 patients. The AUC declined from 70 g.h/ml on
day 1 to 32 g.h/ml on day 28. The results for TSU-68 in
Japanese patients demonstrated a similar toxicity and phar-
macokinetics proWle to Caucasian patients.
Antitumor eVect was observed in some patients in this
clinical study. One patient with adenocarcinoma of the lung
had a minor tumor shrinkage and reduction of tumor
marker levels. In addition, four patients had no disease pro-
gression after one cycle treatment. Although angiogenesis
inhibitors such as TSU-68 have been thought to have little
or no tumor shrinkage, some drugs showed obvious tumor
regression.
Although the primary objective of phase I clinical trial is
not to see response but to determine recommended dose for
phase II clinical trial, tumor response is thought to be an
important factor. Therefore, further studies using this agent
are expected. MTD was not reached in this study, because
DLT was only seen in one patient at 800 mg/m2. We sug-
gest the highest dose level was not the tolerable dose,
because two patients discontinued the treatment for drug-
related toxicities in spite of their being low grade. In addi-
tion, pharmacokinetic data of this level showed no signiW-
cant diVerence compared with other dose levels, and no
dose-dependent increase on days 8 and 29.
In conclusion of this phase I and pharmacokinetic study
with continuous oral bid between meals, TSU-68 has shown
that a multiple receptor tyrosine kinase inhibitor can be
safely administered. The recommended dose for further stud-
ies using this treatment schedule is less than 800 mg/m2 bid.
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